Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02844764 · ClinicalTrials.gov registry record · Phase 2
Safety & Effectiveness of Autologous Regenerative Cell Therapy on Pain & Inflammation of Osteoarthritis of the Hip
A Phase 2 study of Osteoarthritis, sponsored by VivaTech International.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 4,000
- Enrollment target
- 1
- Study location
NCT02844764: Recruiting Phase 2 study of Osteoarthritis, sponsored by VivaTech International.
NCT02844764 is a Phase 2 study of Osteoarthritis that is actively recruiting participants, run by VivaTech International. The registered enrollment target is 4,000 participants, above the 788-participant average among 135 other Osteoarthritis trials with a reported enrollment target (408% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02844764, a Phase 2 study of Osteoarthritis, is actively recruiting participants, sponsored by VivaTech International.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 4,000 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a prospective open-label clinical study of 50 patients to determine safety and treatment potential of autologous cell therapy for pain and inflammation associated with Osteoarthritis of the hip. Follow-up will consist of a larger sample including 4,000 patients.
Primary Outcome
Hip Osteoarthritis Outcome Scores
Conditions Studied
Interventions
- BIOLOGICAL [StroMed + platelet rich plasma (PRP)]
Study Locations (1)
Pennsylvania
- VivaTech International, Inc. - Grove City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4,000 participants |
| Start Date | 2015-07 |
| Est. Completion | 2026-08 |
| Phase | Phase 2 |
What NCT02844764 shows while recruiting
NCT02844764 is an interventional study that assigns participants to a tested intervention. Its 4,000 participants enrollment target places it among the larger protocols in the corpus, above the 788-participant average among 135 other Osteoarthritis trials with a reported enrollment target (408% higher).
The record links to 1 condition, with Osteoarthritis appearing as the primary indexed condition, and to 1 intervention - of which [StroMed + platelet rich plasma (PRP)] is the first listed.
NCT02844764 reports a single indexed study location in Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT02844764 about?
NCT02844764 is a clinical study titled "Safety & Effectiveness of Autologous Regenerative Cell Therapy on Pain & Inflammation of Osteoarthritis of the Hip". This is a prospective open-label clinical study of 50 patients to determine safety and treatment potential of autologous cell therapy for pain and inflammation associated with Osteoarthritis of the hip. Follow-up will consist of a larger sample including 4,000 patients.
What is the current status of trial NCT02844764?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 4,000 participants. The study started on 2015-07. Estimated completion is 2026-08.
What conditions does trial NCT02844764 study?
This clinical trial studies the following conditions: Osteoarthritis.
What interventions are being tested in trial NCT02844764?
The interventions under investigation include: [StroMed + platelet rich plasma (PRP)] (BIOLOGICAL).
Who is sponsoring clinical trial NCT02844764?
This trial is sponsored by VivaTech International, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02844764 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Osteoarthritis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02844764's enrollment target sits among peer trials
4,000 6th of 135 higher than 128 of 135 other Osteoarthritis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Osteoarthritis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Safety & Effectiveness of Autologous Regenerative Cell Therapy on Pain & Inflammation of Osteoarthritis of the Knee
RECRUITING · Phase 2
-
Safety & Effectiveness of Autologous Regenerative Cell Therapy on Pain & Inflammation of Osteoarthritis of the Shoulder
RECRUITING · Phase 2
-
Platelet Rich Plasma Injections In Young And Old Human Subjects
RECRUITING · Phase 2
-
A Mobile Intervention to Reduce Pain and Improve Health-III
RECRUITING · Phase 2
-
An Study to Evaluate Safety and Tolerability of OA-SYS in Subjects With Moderate to Severe Osteoarthritis of the Knee Joint
RECRUITING · Phase 2
-
Adductor Canal Block
ACTIVE NOT RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00227253 · 4,000 participants
Chromosome 18 Clinical Research Center
- NCT00811148 · 4,000 participants
Florida Center for Brain Tumor Research
- NCT00897117 · 4,000 participants
Collecting and Analyzing Tissue Samples From Patients Undergoing Surgery for Non-Small Cell Lung Cancer
- NCT00899301 · 4,000 participants
Collecting and Storing Tissue Samples From Women With or Without Breast Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia